This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
Gilead announced plans in July to pay $300 million for a 49.9% stake in Tizona Therapeutics, with the option to buy the rest of the company for $1.25 billion. Whether Gilead follows through with the acquisition will hinge on how well Tizona's investigational HLA-G inhibitor, TTX-080, fares in early-stage clinical trials.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
October 2020
Volume 10, Issue 10
Volume 10, Issue 10
Gilead Buys into Tizona's Anti–HLA-G Strategy
Jump to section
Advertisement